These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18438700)

  • 1. Romiplostim: an alternative treatment option besides rituximab for the management of steroid refractory idiopathic thrombocytopenic purpura.
    Kapoor S
    J Thromb Thrombolysis; 2009 May; 27(4):453. PubMed ID: 18438700
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia.
    Pohlen M; Sargin B; Zicholl S; Bisping G; Müller-Tidow C; Berdel WE; Mesters R; Koschmieder S
    Eur J Haematol; 2010 Apr; 84(4):362-4. PubMed ID: 20050881
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
    Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
    Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J; Katsandris A; Raptis SD; Mantzourani M
    Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
    Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
    Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
    [No Abstract]   [Full Text] [Related]  

  • 6. Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment.
    Tagariello G; Sartori R; Radossi P; Maschio N; Risato R; Stasi R
    Br J Haematol; 2012 Apr; 157(2):256-8. PubMed ID: 22111882
    [No Abstract]   [Full Text] [Related]  

  • 7. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
    D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
    Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
    [No Abstract]   [Full Text] [Related]  

  • 8. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
    Veneri D; Soligo L; Pizzolo G; Ambrosetti A
    Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
    [No Abstract]   [Full Text] [Related]  

  • 9. High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia.
    Roumier M; Le Burel S; Audia S; Chauchet A; Gousseff M; Hamidou M; Liferman F; Moulis G; Lioger B; Galicier L; Ebbo M; London J; Poutrel S; Terriou L; Zarrouk V; Michel M; Godeau B; Mahevas M
    Am J Hematol; 2021 Feb; 96(2):E43-E46. PubMed ID: 33125750
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature.
    Yassa G; Shakir AR; Jagarlamudi K; Yassa AE
    J Oncol Pharm Pract; 2021 Jan; 27(1):253-257. PubMed ID: 32611269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment.
    Ignatova AA; Demina IA; Ptushkin VV; Khaspekova SG; Shustova ON; Pankrashkina MM; Ryabykh AA; Obydennyi SI; Strelkova OS; Polokhov DM; Seregina EA; Poletaev AV; Ataullakhanov FI; Kireev II; Mazurov AV; Maschan AA; Novichkova GA; Panteleev MA
    Br J Haematol; 2019 Oct; 187(2):e38-e42. PubMed ID: 31422582
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports.
    Gilreath JA; Wei M; Paul S; Parker CJ; Stenehjem DD; Rodgers GM
    J Oncol Pharm Pract; 2019 Apr; 25(3):719-723. PubMed ID: 29357781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 15. [Management of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia, ITP)].
    Kashiwagi H; Tomiyama Y
    Rinsho Ketsueki; 2014 Oct; 55(10):2087-94. PubMed ID: 25297775
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia.
    Álvarez-Román MT; Rivas Pollmar MI; Bernardino JI; Lozano ML; Martín-Salces M; Fernández-Bello I; Jiménez-Yuste V; Butta NV
    AIDS; 2016 Apr; 30(7):1141-2. PubMed ID: 27028144
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
    Ferretti A; Baldacci E; Miulli E; Canichella M; Di Rocco A; Pulsoni A; Martelli M; Serrao A; Chistolini A; Gabriella Mazzucconi M; Foà R; Santoro C
    Br J Haematol; 2019 Sep; 186(6):e217-e219. PubMed ID: 31364154
    [No Abstract]   [Full Text] [Related]  

  • 18. Emperipolesis in a patient receiving romiplostim.
    Cooper N; Bain BJ
    Am J Hematol; 2016 Jan; 91(1):166. PubMed ID: 26407183
    [No Abstract]   [Full Text] [Related]  

  • 19. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New options after first-line therapy for chronic immune thrombocytopenic purpura.
    Burzynski J
    Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.